The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
The 6th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference scheduled to be held from 12th - 15th October 2021 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.
This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Head, Safety Biomarkers, Translational Sciences, Pfizer
Professor of Medicine, University of British Columbia
Head of Precision Medicine, AstraZeneca
Senior Director, Translational Strategy, Bayer
Biomarker Operations Lead, Pfizer
Pathologist, Companion Diagnostics, Agilent Technologies
Senior Manager, Biomarker Clinical Assay Lead, Pfizer
Senior Scientific Program Manager, Agilent Technologies, USA
Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.
Business Development Manager, Owlstone Medical
Lead Biomarker Discovery Scientist, Owlstone Medical
Associate Director, Medical Scientific Affairs, Sysmex Inostics